Your browser doesn't support javascript.
loading
Accounting for tumor heterogeneity when using CRISPR-Cas9 for cancer progression and drug sensitivity studies.
Olive, Jessica F; Qin, Yuanbo; DeCristo, Molly J; Laszewski, Tyler; Greathouse, Frances; McAllister, Sandra S.
Afiliación
  • Olive JF; Department of Medicine, Division of Hematology, Brigham and Women's Hospital, Boston, Massachusetts, United States of America.
  • Qin Y; Department of Medicine, Harvard Medical School, Boston, Massachusetts, United States of America.
  • DeCristo MJ; Department of Medicine, Division of Hematology, Brigham and Women's Hospital, Boston, Massachusetts, United States of America.
  • Laszewski T; Department of Medicine, Harvard Medical School, Boston, Massachusetts, United States of America.
  • Greathouse F; Department of Medicine, Division of Hematology, Brigham and Women's Hospital, Boston, Massachusetts, United States of America.
  • McAllister SS; Department of Medicine, Harvard Medical School, Boston, Massachusetts, United States of America.
PLoS One ; 13(6): e0198790, 2018.
Article en En | MEDLINE | ID: mdl-29897959
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Sistemas CRISPR-Cas / Neoplasias / Antineoplásicos Tipo de estudio: Diagnostic_studies Límite: Animals / Humans Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Sistemas CRISPR-Cas / Neoplasias / Antineoplásicos Tipo de estudio: Diagnostic_studies Límite: Animals / Humans Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos